Maxitrol

Neomycin sulfate, the active ingredient in Maxitrol, is a combination antibiotic corticosteroid presented as an ophthalmic suspension for ocular use. It treats bacterial eye infections and associated inflammation in patients of all ages, and the formulation also contains Polymyxin B sulfate and Dexamethasone to provide broad‑spectrum antibacterial activity together with anti‑inflammatory effects.

GNH USA supplies Maxitrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable quality and regulatory compliance across global markets.

Maxitrol is a combination antibiotic corticosteroid indicated for several ocular conditions where bacterial infection and inflammation coexist.

Bacterial conjunctivitis: reduces bacterial load and associated inflammation, promoting faster symptom resolution. Ocular inflammation (non‑infectious): diminishes swelling, redness, and discomfort caused by inflammatory processes. Post‑operative eye inflammation: controls inflammation and helps prevent secondary infection after ocular surgery.

Adverse ocular reactions have been reported with Maxitrol and can be classified by frequency.

Common Side Effects: - Eye irritation or burning sensation - Itching or mild redness - Temporary blurred vision - Mild increase in intra‑ocular pressure - Tearing or discharge

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis) - Corneal ulceration or perforation - Persistent or worsening vision loss - Secondary ocular infection with resistant organisms - Elevated intra‑ocular pressure leading to glaucoma

Before prescribing Maxitrol, clinicians should consider several safety and handling points.

Assess for viral or fungal eye infections: avoid use as it may worsen these infections. Monitor intra‑ocular pressure: corticosteroid component can raise pressure, especially with prolonged use. Use with caution in patients with known hypersensitivity to any component: discontinue if reaction occurs. Limit duration of therapy: prolonged use increases risk of cataract formation and glaucoma. Avoid use in children unless directed: pediatric eyes are more susceptible to steroid‑induced side effects. Store at room temperature: keep in original container, protect from light and moisture.

Maxitrol may interact with other ophthalmic or systemic agents; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Systemic corticosteroids: additive immunosuppression may increase infection risk. - Other topical ophthalmic antibiotics: may cause antagonistic effects or increased toxicity. - Antiglaucoma medications (e.g., beta‑blockers): steroid‑induced pressure rise can counteract their effect.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may increase risk of corneal toxicity. - Anticholinergic eye drops: may reduce tear production, enhancing irritation. - Systemic aminoglycosides: potential additive nephrotoxicity if systemic absorption occurs (rare).